First quarter results 2015
Announced on Friday 24 April 2015
- Download press release & pipeline update (PDF 438kb)
- Download presentation (PDF 1014kb)
- Clinical trials appendix (PDF 2979kb)
WebcastView the webcast
Pascal Soriot, Chief Executive Officer, commenting on the results, said:
"Our encouraging performance in the quarter supports our full year guidance. Total Revenue grew by 1%, with the growth platforms representing 56%, after particularly strong results in Emerging Markets and with Brilinta/Brilique. Our co-commercialisation agreement for Movantik in the US was a good illustration of how we will bring important medicines to patients and externalisation value to our shareholders.
"Our pipeline progressed well in each of our therapy areas. Highlights included the positive top-line results from the Phase III PINNACLE programme for our respiratory medicine PT003 and data from the PEGASUS study for Brilinta/Brilique in cardiovascular disease. We received two submission acceptances for new medicines, two FDA Orphan-Drug and two Fast-Track designations. We look forward to presenting data through the year.
"We also continued to reinforce our Oncology franchise and now have 72 trials underway, including 31 in Immuno-Oncology. The latest AZD9291 data, which showed strong clinical benefit of 13.5 months progression-free survival, and the Fast-Track designation by the FDA for MEDI4736, both for patients with lung cancer, illustrate the rapid progress we are making in this area. Our strategic collaboration with Celgene, a leader in haematology, will maximise the potential of our Immuno-Oncology assets in the very important haematology indications, and our collaboration with Innate Pharma will further strengthen our Immuno-Oncology franchise.”
A recording of the analyst presentation and Q&A session will be available until 15:30BST Thursday 7 May, on the following numbers:
|UK local||0800 953 1533||75183821#|
|US (freephone)||1 866 247 4222||75183821#|
|International||+44 1452 55 00 00||75183821#|